Journal Mobile Options
Table of Contents
Vol. 40, No. 2, 2001
Issue release date: August 2001

Transrectal High Intensity Focused Ultrasound for the Treatment of Localized Prostate Cancer: Factors Influencing the Outcome

Gelet A. · Chapelon J.Y. · Bouvier R. · Rouvière O. · Lyonnet D. · Dubernard J.M.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Objectives: Efficacy evaluation of high intensity focused ultrasound (HIFU) treatment for localized prostate cancer and identification of the factors affecting the outcome. Patients and Methods: 102 patients with prostate cancer stage T1–T2 and noncandidates for radical prostatectomy have been treated with HIFU (Ablatherm™, EDAP–Technomed). The disease progression (failure) was strictly defined by any positive sample at control biopsies, whatever the prostate–specific antigen (PSA) level, or by 3 consecutive increases in PSA levels in case of negative biopsies. Results: At inclusion, patients’ baseline characteristics were (mean ± standard deviation): age 70.8 (±6.13) years, PSA 8.38 (±4.8) ng/ml, prostate volume 33.3 (±16.71) cm3. The population mean follow–up was 19 months (3–76 months). The overall success rate was 66%. Statistically significant variations of the overall success with a more favorable outcome were observed when (1) the initial PSA level was ≤10 ng/ml (73 vs. 50%, p = 0.02), (2) the Gleason score was ≤6 (81 vs. 46%, p<0.001) and (3) the pretreatment sextant biopsy evidenced 1–4 positive samples (68 vs. 40%, p = 0.01). Conclusion: Results observed after HIFU treatment in localized prostate cancer are now challenging those obtained after radiation therapy. The success rate is influenced by disease–related prognostic factors.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Brasso K, Friss S, Juel K, Jorgensen T, Iversen P: Mortality of patients with clinically localized prostate cancer treated with observation for 10 years or longer: A population based registry study. J Urol 1999;161:524–528.
  2. Brasso K, Friss S, Juel K, Jorgensen T, Iversen P: The need for hospital care of patients with clinically localised prostate cancer managed by non curative intent: A population based registry study. J Urol 2000;163:1150–1154.
  3. Neulander EZ, Duncan RC, Tiguert R, Posey JT, Soloway MS: Deferred treatment of localised prostate cancer in elderly: The impact of the age and stage at the time of diagnosis on treatment decision. Br J Urol 2000;85:699–704.
  4. Chapelon JY, Margonari J, Theillere Y, Gorry F, Vernier F, Blanc E, Gelet A: Effects of high–energy focused ultrasound on kidney tissue in the rat and the dog. Eur Urol 1992;22: 147–152.
  5. Chapelon JY, Margonari J, Vermier F, Gorry F, Ecochard R, Gelet A: In vivo effects of high intensity ultrasound on prostatic adenocarcinoma Dunning R3327. Cancer Res 1992;52: 6353–6457.
  6. Gelet A, Chapelon JY, Margonari J, Theillere Y, Gorry F, Souchon R, Bouvier R: High intensity focused ultrasound: Experimentation on canine prostate. J Endourol 1993;7:249–253.
  7. Gelet A, Chapelon JY, Bouvier R, Souchon R, Pangaud C, Abdelbrahim AF, Cathignol D, Dubernard JM: Treatment of prostate cancer with transrectal focused ultrasound: Early clinical experience. Eur Urol 1996;29:174–183.
  8. Gelet A, Chapelon JY, Bouvier R, Pangaud C, Lasne Y: Local control of prostate cancer by transrectal high intensity focused ultrasound therapy: Preliminary results. J Urol 1999;161: 156–162.
  9. Chavrier F, Chapelon JY, Gelet A, Cathignol D: Modeling of HIFU induced lesions in the presence of cavitation bubbles. J Acoust Soc Am 2000;108:1–7.

    External Resources

  10. Fry FJ, Hossoff G, Eggleton RC, Dunn F: Threshold ultrasonic dosages for structural changes in mammalian brain. J Acoust Soc Am 1970;48:1413–1417.

    External Resources

  11. Frizzel LA: Threshold dosages for damage to mammalian liver by high intensity focused ultrasound. IEEE Trans Ultrasound Fenoelec Freq Contr 1988;35:578–581.
  12. Ter Haar GR, Sinnett D, Rivens I: High intensity focused ultrasound: A surgical technique for the treatment of discrete liver tumors. Phys Med Biol 1989;34:1743–1750.
  13. Beerlage HP, Thüroff F, Debruyne FMJ, Chaussy C, De la Rosette JJMCH: Transrectal high–intensity focused ultrasound using the Albathem device in the treatment of localized prostate cancer. Urology 1999;54:273–277.
  14. Gelet A, Chapelon JY, Bouvier R, Rouvière O, Lasnes Y, Lyonnet D, Dubernard JM: Transrectal high intensity focused ultrasound: Minimally invasive therapy of localized prostate cancer. J Endourology 2000;14:513–522.

    External Resources

  15. Pearson JD, Carter HB: Natural history of changes in prostate specific antigen in early stage prostate cancer. J Urol 1994;152:1743– 1747.
  16. Stamey TA, Yemoto CM, Mc Neal JE, Sigal BM, Johnstone IM: Prostate cancer is highly predictable: A prognostic equation based on all morphological variables in radical prostatectomy specimen. J Urol 2000;163:1155–1160.
  17. Hanks GE, Hanlon AL, Schultheiss TE, Freedman GM, Hunt M, Pinover WH, Movsas B: Conformal external beam treatment of prostate cancer. Urology 1997;50:87–92.
  18. Freiha FS, Bagshaw MC: Carcinoma of the prostate: Results of post–irradiation biopsy. Prostate 1984;5:19–25.

    External Resources

  19. Kaplan I, Prestidge BR, Cox RS, Bagshaw MA: Prostate specific antigen after irradiation for prostatic carcinoma. J Urol 1990;144: 1172–1176.
  20. D’Amico AV, Schultz D, Schneider L, Hurwitz M, Kantoff PW, Richie JP: Comparing prostate specific antigen outcomes after different types of radiotherapy management of clinically localized prostate cancer highlights the importance of controlling for established prognostic factors. J Urol 2000;163:1797–1801.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50